Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387163 · ClinicalTrials.gov registry record
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 402
- Enrollment target
NCT03387163: Completed study, sponsored by Novartis Pharmaceuticals.
NCT03387163 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 402 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03387163 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 402 participants
- Enrollment target
Study Summary
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.
Primary Outcome
Kansas City Cardiomyopathy Questionnaire (KCCQ) - self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life in patients with heart failure.
Interventions
- DRUG Sacubitril/Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2019-06-21 |
What the finished NCT03387163 record still lists
NCT03387163 is an observational study that tracks outcomes without assigning an intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Sacubitril/Valsartan is the first listed.
NCT03387163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03387163 about?
NCT03387163 is a clinical study titled "Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure". Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.
What is the current status of trial NCT03387163?
This trial is currently completed. The enrollment target is 402 participants. The study started on 2018-02-09. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT03387163?
The interventions under investigation include: Sacubitril/Valsartan (DRUG).
Who is sponsoring clinical trial NCT03387163?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI